FibroGen
Winny Wong is a highly experienced quality control professional with over 17 years of expertise in the biotechnology and pharmaceuticals industry. Currently serving as a Sr QC Specialist II at FibroGen, Inc. since July 2017, Winny previously held positions at BioMarin, Genentech, Cell Genesys, and Progenitor Cell Therapy. Notable skills include proficiency in protein concentration determination, enzyme activity assays, method validation, microbial testing, and environmental monitoring in cleanroom settings. Winny holds a Bachelor of Science in Biological Sciences from the University of California, Davis.
This person is not in the org chart
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.